News & Events

Increasing the Efficiency of Clinical Trials

In this interview, Georg Schulz, EVP of Clinical Services & Senior Director of Corporate Development at Tanner Pharma Group speaks with The Medicine Maker about increasing the efficiency of clinical trials. He also offers his perspective on the trends and challenges affecting clinical trials, including the growing prevalence of digital and decentralized trials and COVID-19…

Increasing cancer treatment access in low and middle-income countries

Low and middle-income countries typically have lower survival rates from cancer due to a lack of treatments, diagnosis, and support services. These issues are intensified for those living in remote communities. We learn more about Tanner’s partnership with The Max Foundation and how together the organizations have been able to deliver cancer treatments throughout developing…

Navigating registration and commercialization challenges in Latin America

Supplying medical products to Latin America presents a range of challenges. From registration requirements to logistics, supply maintenance and promotion, the complexities are further exacerbated by country-specific regulations, politics, healthcare systems, and more. Tanner Pharma recognized these challenges and started the TannerLAC division over 20 years ago to serve as a partner for pharmaceutical companies…

Unbridled Gratitude | Breanna Floyd 

There are two things Breanna Floyd brings to work in the morning and takes home in the evening – a smile and a sense of gratitude. Unbridled gratitude, actually. And why wouldn’t she? Breanna sees no reason not to have both, being fresh out of college and still working for an organization she regards as…

The Business of Helping People | Jonathan Bracey 

Jonathan Bracey, or JB as many call him, has become a staple face at Tanner Pharma Group. He currently serves as the company’s Executive Vice President of Corporate Development supporting the 4 core commercial divisions, though his job has entailed a bit of everything over the years.  In the early stages of his career path…

Tanner Pharma Group to Distribute Novel Diagnostic Test in Latin America

TannerLAC UK Limited (“TannerLAC”), a part of Tanner Pharma Group, and Epimune Diagnostics (“Epimune”), a molecular diagnostic company, recently partnered to distribute the innovative diagnostic test, i.Mune TBNK®, in Latin America. i.Mune TBNK® is an IVD product that quantifies CD3+, CD4+, CD8+ T-, B- and NK lymphocytes in fresh blood or a dried blood spot…

Managed access programs explained with TannerMAP

Tanner’s Managed Access Program (MAP) division specializes in increasing access to life-saving treatments for patients who would otherwise be unable to access them, either via pre-approval access programs or global donation programs. TannerMAP also develops and delivers access programs for specific medicines from manufacturer partners. TannerMAP focuses on providing access to medicines that are commercialized…

Crisis response: meeting urgent demand for PPE and tests in the pandemic

As Covid-19 swept across the world, Tanner Pharma Group started receiving near-insurmountable requests from multiple industries for testing kits and PPE. Learn more about how Tanner met demand through the development of a dedicated subdivision, TannerGMS, and learn what the future holds for diagnostics and PPE as we emerge from the shadow of the Covid-19.…

Partnering to Respond to a Possible Nuclear Threat

Originally posted on May 25, 2022 on PharmaceuticalExecutive.com. Steve Scalia, Bob Mulroy, John L. McManus Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity. In early March, an explosion at Ukraine’s Zaporizhzhia nuclear power plant after intense Russian shelling had the world…

Birmingham Biotech and Tanner Pharma Group Enter Distribution Partnership for Innovative Nasal Spray in Latin America

Birmingham, UK, 31st May 2022 / Sciad Newswire / Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and TannerLAC UK Limited (“TannerLAC”), a part of Tanner Pharma Group, have entered into a license agreement for the distribution of Norizite™ Nasal Spray in Latin America. TannerLAC provides pharmaceutical, biotech, and healthcare companies with a single-point partner…

Tanner Pharma Expands Operations to Ireland

Tanner Pharma announced today its expansion to Ireland with the opening of a new office space in Cork, the country’s third largest city. The new location was selected after many months of travel and research by Tanner’s executive team. With the withdrawal of the United Kingdom from the European Union, it was essential for Tanner to maintain a presence in…

Charlotte Company Stockpiling Drug in Europe to Treat Radiation and Chemical Exposure

The move was made due to Russia’s invasion of Ukraine and the escalating potential for incidents that would require the medication. Originally posted on WCNC.com. Author: Curtis Carden | Published: 9:25 PM EDT April 4, 2022 | Updated: 11:27 PM EDT April 4, 2022 CHARLOTTE, N.C. — An international distributor of medicines, based in Charlotte, is upping its…

Q1 2022 Global Team Event!

Tanner Pharma Increases Europe-Based Inventory of Leukine® to Expand Availability and Enhance Response to Potential Radiation Exposure Due to the Ongoing Conflict in Ukraine

Leukine is FDA Approved to Treat Acute Radiation Syndrome (ARS) and Recommended in EMEA/CPMP Guidance to Treat Systemic Sulfur Mustard (HD) Gas Exposure LONDON–(BUSINESS WIRE)–Tanner Pharma Group, an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe. This action is being…

Tanner Pharma Featured in the EDPNC’s 2021 Annual Report as Top Global Reach Exporter

Read original publication on the EDPNC website. TRADE TEAM HELPS COMPANY IMPROVE GLOBAL ACCESS TO MEDICINES Headquartered in Charlotte, Tanner Pharma Group is a rapidly growing company with local roots and a global mission — to improve lives by increasing access to medicine around the world. Tanner teams up with U.S. pharmaceutical, biotech and health…

Early access programs: how real-world data capture helps regulatory approval

While clinical trials can prove that a medical product is safe and effective in a controlled environment, the vital data for how a new medicine will perform in the real world is often lacking. Learn more about the connection between real-world data capture and early access programs, and the role this plays in the approval…

Global access programs: meeting urgent medical needs

The mission of Tanner’s global access programs (GAP) division is to meet immediate medical needs for patients regardless of their geographical location. The division’s work includes addressing medicine market withdrawal, post-clinical trial solutions, mitigating drug shortages and managing medicine supply on a Named Patient basis. To learn more, we speak to Maryori Alvarenga, EVP of…

The benefits of early access programs

Patients living with critical illnesses may require access to medicines that are unavailable to them for various reasons. Life-changing treatments might take years to pass the necessary regulatory approvals in certain countries, if at all. Tanner enables patient access to innovative medicines through the creation and implementation of early access programs. These programs are compliant…